Baxdrostat (Baxfendy), originating from Omega portfolio company CinCor Pharma, was approved in the US as the first aldosterone synthase inhibitor for hypertension.
CinCor Pharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and renal diseases, particularly through its lead product candidate, CIN-107, an aldosterone synthase inhibitor
CinCor Pharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and renal diseases, particularly through its lead product candidate, CIN-107, an aldosterone synthase inhibitor.